Clinical Trial

A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The objective of this study is to determine best overall response rate (BOR) based on radiological assessment per RECIST v1.1 to combination of S-1 and Osimertinib in treatment-resistant EGFR mutant lung cancer.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-03-06; most recent amendment 2026-06-17.
Status change: Recruiting → Active, Not Recruiting 2025-09-01
Status change: Not Yet Recruiting → Recruiting 2023-09-24
Trial Details
NCT Number NCT05773092
Lead Sponsor National Cancer Centre, Singapore
Collaborators: Taiho Pharmaceutical Co., Ltd.
Conditions NSCLC
Enrollment 30 participants
Start Date 2023-08-01
Primary Completion 2025-10-24 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-22